Bestmade Natural Products Silicea 8x

Dosage for Silica as an allergenic extract is highly individualized and must be determined by an allergist or immunologist based on the patient's level of sensitivity.

• Diagnostic Testing (Skin Prick): Usually involves a single drop of a 1:10 or 1:20 w/v (weight/volume) concentration applied to the forearm or back, followed by a superficial puncture of the skin.
• Therapeutic Immunotherapy: Follows a two-phase schedule:
• Build-up Phase: Starts with an extremely low dose (e.g., 0.05 mL of a 1:100,000 dilution). Doses are increased weekly or bi-weekly over 3 to 6 months until the 'maintenance dose' is reached.
• Maintenance Phase: The highest tolerated dose (e.g., 0.5 mL of a 1:100 or 1:10 dilution) is administered every 2 to 4 weeks for a period of 3 to 5 years.

Silica extracts may be used in children, typically those aged 5 years and older, who demonstrate significant allergic symptoms.

• Dosing Logic: Pediatric dosing follows the same escalation logic as adult dosing, though clinicians may start at even lower concentrations if the child is deemed 'highly sensitive.'
• Safety: Children must be monitored even more closely for signs of systemic reactions, as they may not be able to articulate early symptoms of anaphylaxis (a severe, life-threatening allergic reaction).

Renal Impairment

No specific dose adjustments are typically required for patients with kidney disease, as the systemic load of the extract is extremely low. However, if a patient is experiencing acute renal failure, immunotherapy should be paused until they are stable.

Hepatic Impairment

There are no known requirements for dosage adjustment in patients with liver disease. The metabolism of allergenic extracts is primarily local and lymphatic rather than hepatic.

Elderly Patients

Caution is advised in elderly patients, particularly those with underlying cardiovascular disease. The use of Silica extracts in patients over 65 should be carefully weighed against the risk of the patient not being able to tolerate the emergency medications (like epinephrine) required to treat a potential severe reaction.

Silica allergenic extracts are NOT for self-administration at home.

• Administration Site: Injections are given subcutaneously in the posterior aspect of the upper arm.
• Observation Period: Patients MUST remain in the doctor's office for at least 30 minutes after every injection. Most fatal reactions to allergenic extracts occur within this window.
• Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze, as this can denature the proteins and render the extract ineffective or dangerous.

If a dose in the build-up phase is missed, the next dose may need to be reduced to ensure safety.

• 1 week late: Continue with the planned dose.
• 2-3 weeks late: Repeat the previous dose or reduce it by one level.
• Over 4 weeks late: The clinician may need to restart the escalation from a much lower concentration.

An 'overdose' in the context of Silica extracts usually refers to an injection of a concentration that is too high for the patient's current tolerance level.

• Symptoms: Rapid onset of hives, swelling of the throat, wheezing, low blood pressure, and fainting.
• Emergency Measures: Immediate administration of epinephrine (0.3 mg intramuscularly), followed by antihistamines, corticosteroids, and emergency transport to a hospital.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not attempt to self-administer these extracts unless specifically trained and authorized for a home-use product (which is rare for non-standardized extracts).

Most patients receiving Silica extracts will experience local reactions at the site of administration. These are generally considered a sign that the immune system is responding to the treatment.

• Local Swelling: A raised area (wheal) at the injection site that may be 1-3 cm in diameter.
• Erythema (Redness): Redness surrounding the injection site that typically fades within 24 hours.
• Pruritus (Itching): Intense itching at the site of the injection or skin test.
• Tenderness: The arm may feel sore or 'bruised' for several hours after the procedure.

• Large Local Reactions: Swelling that exceeds 5-10 cm in diameter or involves the entire upper arm. This may require an adjustment in the next dose.
• Fatigue: Many patients report feeling unusually tired for several hours after an immunotherapy session.
• Headache: Mild to moderate tension-type headaches.
• Nasal Congestion: A temporary 'flare' of allergy symptoms shortly after the injection.

• Urticaria (Hives): Generalized hives appearing on parts of the body away from the injection site.
• Angioedema: Swelling of the deeper layers of the skin, often around the eyes or lips.
• Lymphadenopathy: Swelling of the lymph nodes in the armpit (axilla) on the side of the injection.

> Warning: Stop taking Silica and call your doctor immediately or seek emergency care if you experience any of these symptoms of anaphylaxis:

1. 1Respiratory Distress: Difficulty breathing, wheezing, or a high-pitched sound when breathing (stridor).
2. 2Throat Tightness: A feeling that the throat is closing or difficulty swallowing.
3. 3Cardiovascular Collapse: A sudden drop in blood pressure, feeling faint, dizzy, or losing consciousness.
4. 4Rapid Pulse: A racing heart (tachycardia) accompanied by a sense of doom.
5. 5Cyanosis: A bluish tint to the lips, face, or fingernails indicating lack of oxygen.

With prolonged use (3-5 years), Silica immunotherapy is generally well-tolerated. However, some patients may develop 'granulomas' (small, firm bumps) at the injection sites if the extract contains certain insoluble particles. There is no evidence that long-term use of allergenic extracts increases the risk of autoimmune diseases or cancer.

While Silica as a non-standardized extract may not have a specific 'Black Box' on every label, the FDA requires a general warning for all allergenic extracts regarding the risk of Severe Systemic Allergic Reactions.

• Summary: Silica extracts can cause life-threatening anaphylaxis. They must only be administered by healthcare professionals in settings equipped with emergency supplies (epinephrine, oxygen, IV fluids). Patients with unstable asthma are at a significantly higher risk of fatal outcomes.

Report any unusual symptoms to your healthcare provider. Even a 'large' local reaction should be reported, as it may predict a systemic reaction in the future.

Silica allergenic extracts are potent biological substances. Their use is restricted to diagnostic and therapeutic procedures under strict medical supervision. Patients should be in their baseline state of health (no active infections or asthma flares) before receiving a dose.

No specific FDA black box warning is currently assigned specifically to 'Silica' as an isolated entity, but it falls under the mandatory class-wide warnings for ALL Allergenic Extracts. These warnings emphasize that:

1. 1The product can cause anaphylaxis.
2. 2It must be administered in a medical facility.
3. 3Patients must be observed for at least 30 minutes post-injection.
4. 4It may not be suitable for patients on beta-blockers.

• Anaphylaxis Risk: This is the primary concern. Patients with a history of severe reactions to very small amounts of allergens are at the highest risk.
• Asthma Status: Patients with uncontrolled or severe asthma should not receive Silica immunotherapy, as they are more likely to have a fatal reaction if anaphylaxis occurs.
• Cardiovascular Disease: Patients with significant heart disease may not be able to tolerate the physiological stress of an allergic reaction or the effects of the epinephrine used to treat it.
• Autoimmune Disorders: Use with caution in patients with active autoimmune diseases, as immunotherapy can theoretically cause a flare of the underlying condition.

• Pre-Injection Assessment: Before every dose, the clinician must check for symptoms of illness or changes in asthma control (e.g., peak flow meter readings).
• Post-Injection Observation: Mandatory 30-minute wait time in the clinic.
• Site Inspection: The injection site should be checked for large local reactions before the patient leaves.
• Lung Auscultation: If the patient reports chest tightness, the clinician should listen to the lungs for wheezing.

Silica itself does not cause sedation. However, if a patient experiences a systemic reaction or is given antihistamines to treat a local reaction, their ability to drive or operate machinery may be impaired. It is generally recommended to wait until you are sure you feel normal before driving after an injection.

Alcohol should be avoided for several hours before and after receiving a Silica injection. Alcohol can increase blood flow to the skin (vasodilation), which may speed up the absorption of the allergen and increase the risk of a systemic reaction.

If a patient experiences a severe systemic reaction, the healthcare provider will re-evaluate the risks and benefits of continuing Silica immunotherapy. In many cases, the treatment is discontinued or the dose is significantly reduced. There is no 'withdrawal syndrome' associated with stopping Silica extracts.

> Important: Discuss all your medical conditions with your healthcare provider before starting Silica, especially any history of heart problems or breathing difficulties.

• Beta-Blockers (e.g., Propranolol, Metoprolol): These medications are generally contraindicated in patients receiving Silica immunotherapy. Beta-blockers can make an allergic reaction more severe and, more importantly, they block the effects of epinephrine (adrenaline), which is the primary treatment for life-threatening anaphylaxis.

• ACE Inhibitors (e.g., Lisinopril, Enalapril): These blood pressure medications may increase the risk of more severe systemic reactions or interfere with the body's natural compensatory mechanisms during an allergic event.
• MAO Inhibitors (e.g., Phenelzine): These can interfere with the metabolism of emergency medications used to treat reactions.

• Antihistamines (e.g., Loratadine, Cetirizine): While not dangerous, taking antihistamines before a diagnostic skin test will lead to a 'false negative' result because the medication prevents the wheal and flare reaction. Antihistamines should be stopped 3 to 7 days before testing.
• Tricyclic Antidepressants (e.g., Amitriptyline): These may potentiate the effects of epinephrine if an emergency occurs, leading to dangerously high blood pressure.

• Heavy Meals: It is advised not to eat a very large or heavy meal immediately before an injection, as this can complicate the management of gastrointestinal symptoms of anaphylaxis (like nausea and vomiting).
• Alcohol: As mentioned, alcohol can increase the rate of allergen absorption through vasodilation.

• St. John’s Wort: May theoretically interact with the metabolism of other medications used in the clinic.
• High-Dose Vitamin C: Some studies suggest very high doses of Vitamin C may have a mild antihistamine effect, which could potentially interfere with diagnostic testing accuracy.

• Skin Prick Tests: Silica will interfere with any skin test results if the patient is currently undergoing immunotherapy with the same or related extracts.
• Total IgE: Immunotherapy may cause a transient increase in total IgE levels before they eventually decline over several years.

Mechanism of Interactions:

Most interactions with Silica extracts are pharmacodynamic (how the drugs affect the body) rather than pharmacokinetic. For example, beta-blockers do not change the level of Silica in the blood; instead, they change how the heart and lungs respond to the chemicals released during an allergy.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete list is vital for your safety during immunotherapy.

Silica allergenic extracts must NEVER be used in the following circumstances:

1. 1Previous Severe Systemic Reaction: If a patient has had a near-fatal reaction to Silica or a similar extract in the past.
2. 2Uncontrolled Asthma: Patients with an FEV1 (forced expiratory volume) consistently below 70% of their predicted value are at an unacceptably high risk of death from an allergic reaction.
3. 3Acute Infection: If a patient has a fever or a respiratory infection, the immune system is already 'primed,' and the risk of a reaction to the extract is significantly higher.
4. 4Beta-Blocker Therapy: Due to the inability to effectively treat anaphylaxis with epinephrine.

Conditions requiring a careful risk-benefit analysis include:

• Severe Atopic Dermatitis: May make skin testing difficult to interpret.
• Pregnancy: While not strictly contraindicated if a patient is already on a stable maintenance dose, starting new Silica immunotherapy during pregnancy is generally avoided due to the risk of fetal hypoxia (lack of oxygen) if the mother has a systemic reaction.
• Active Malignancy: The immune system may be compromised, making the response to immunotherapy unpredictable.

Patients allergic to Silica-rich plants, such as Horsetail (Equisetum) or certain grasses, may show cross-reactivity with Silica extracts. Clinicians should be aware that a patient highly sensitive to one 'Non-Standardized Plant Allergenic Extract' may have a lower threshold for reactions to others.

> Important: Your healthcare provider will evaluate your complete medical history, including your current lung function and medication list, before prescribing Silica.

Silica allergenic extracts are categorized as Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women.

• Risk Summary: The primary risk during pregnancy is not the Silica itself, but the potential for a systemic reaction (anaphylaxis) in the mother. This can cause a sudden drop in blood pressure and uterine contraction, leading to fetal distress or miscarriage.
• Clinical Recommendation: Most allergists recommend continuing Silica immunotherapy if the patient is already on a stable, well-tolerated maintenance dose. However, increasing the dose or starting treatment for the first time is usually deferred until after delivery.

It is not known whether Silica components or the antibodies produced during treatment are excreted in human milk. However, because the extract is administered in minute quantities and works locally/lymphatically, it is generally considered safe to continue Silica treatment while breastfeeding. No adverse effects have been documented in nursing infants.

Silica extracts are used in children, but the decision must be made with caution.

• Age Limit: Generally not recommended for children under 5 years of age because they may be unable to communicate the early symptoms of a systemic reaction.
• Growth Effects: There is no evidence that allergenic extracts like Silica affect growth or development in children.
• Benefit: Early intervention with immunotherapy in children may prevent the 'allergic march' (the progression from hay fever to asthma).

In patients over 65, the risks of Silica immunotherapy often outweigh the benefits.

• Cardiovascular Risk: Older adults are more likely to have underlying heart disease, making them poor candidates for epinephrine if a reaction occurs.
• Polypharmacy: The higher likelihood of being on beta-blockers or ACE inhibitors increases the danger of treatment.
• Clearance: While renal clearance is reduced in the elderly, this is of minimal clinical significance for Silica extracts.

Specific dose adjustments for Silica are not established for patients with renal impairment. However, clinicians should monitor these patients for overall fluid balance and stability, as a systemic reaction could place additional stress on the kidneys.

No adjustments are required for patients with liver disease. The processing of Silica antigens occurs via the immune system and local tissue enzymes, not the cytochrome P450 system in the liver.

> Important: Special populations require individualized medical assessment. Always inform your specialist if you are pregnant, planning to become pregnant, or have chronic kidney or liver issues.

Silica, as a Non-Standardized Plant Allergenic Extract, operates through complex immunological modulation. Upon subcutaneous administration, the Silica antigens are captured by dendritic cells (antigen-presenting cells). These cells migrate to the regional lymph nodes and present the Silica peptides to naive T-cells.

In an allergic individual, this process normally favors a Th2 response. However, controlled, repetitive exposure via immunotherapy induces peripheral tolerance. This involves:

1. 1T-cell Anergy: Making the T-cells less responsive to the allergen.
2. 2Treg Induction: Increasing the production of IL-10 and TGF-beta, which suppress inflammation.
3. 3B-cell Class Switching: Shifting production from IgE (which causes allergies) to IgG4 (which blocks the allergic response).

• Onset of Effect: Diagnostic skin test results appear in 15-20 minutes. For therapeutic effects, it typically takes 6 to 12 months of consistent treatment to see a reduction in symptoms.
• Duration of Effect: The benefits of a completed 3-5 year course of Silica immunotherapy can last for several years after the treatment is discontinued.
• Dose-Response: There is a clear dose-response relationship; higher maintenance doses are generally more effective but carry a higher risk of side effects.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous/Intradermal) |

| Protein Binding | Minimal (Antigens bind to IgE/IgG) |

| Half-life | Local persistence: Days; Immunological effect: Years |

| Tmax | 15-30 minutes (for local histamine release) |

| Metabolism | Proteolytic degradation in tissues |

| Excretion | Renal (as small peptide fragments) |

• Molecular Formula: Primarily SiO2 (Silicon Dioxide) within a biological matrix.
• Molecular Weight: Varies (Complex mixture of proteins and minerals).
• Solubility: Formulated as an aqueous or glycerinated extract.
• Description: A clear to slightly turbid liquid, ranging from colorless to light amber.

Silica belongs to the Non-Standardized Plant Allergenic Extract [EPC] class. It is grouped with other allergenic extracts used for 'In Vivo Diagnostic Biologicals' and 'Allergenic Desensitization Agents.'